Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Share-based Compensation (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Share-based Compensation for 7 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 23.78% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.5 million, a 14.33% decrease, with the full-year FY2025 number at $12.5 million, down 14.33% from a year prior.
  • Share-based Compensation was $3.1 million for Q4 2025 at Fulcrum Therapeutics, down from $3.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.3 million in Q2 2024 to a low of $2.1 million in Q1 2021.
  • A 5-year average of $3.3 million and a median of $3.4 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 126.18% in 2021, then tumbled 33.82% in 2025.
  • Fulcrum Therapeutics' Share-based Compensation stood at $3.8 million in 2021, then decreased by 13.76% to $3.3 million in 2022, then rose by 5.44% to $3.4 million in 2023, then decreased by 28.18% to $2.5 million in 2024, then rose by 23.78% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Share-based Compensation are $3.1 million (Q4 2025), $3.4 million (Q3 2025), and $2.9 million (Q2 2025).